Skip to main content
    R

    Revolution Medicines Inc (RVMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $166.87
    -5.42 (-3.15%)

    Market Cap: $37.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Revolution Medicines Inc (RVMD) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Revolution Medicines (RVMD) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Revolution Medicines reported EPS of -$1.90, above the -$2.34 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    22%(6/27)
    Avg Surprise
    -12.13%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.87
    Range-$3.46 - -$0.85
    25 analysts
    Revenue Consensus
    $227.96M
    Range$43.73M - $528.36M
    23 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.81
    Range-$2.35 - $0.38
    11 analysts
    EPS Estimate DriftChange to current
    90d ago-$1.90+57.4%
    60d ago-$1.84+55.9%
    30d ago-$1.84+55.9%
    7d ago-$1.83+55.7%
    Current-$0.81
    Revenue Consensus
    $462.04M
    Range$137.00M - $685.00M
    10 analysts

    Next Report

    RVMD has an expected report date of Feb 23, 2027.

    RVMD Earnings Call

    The latest RVMD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 27 quarters below that had an estimate, RVMD beat 6 and missed 21. The widest gap in the table came in the quarter ended Mar 31, 2020, when EPS landed 105.56% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.90-$2.34-$3.24 - -$2.07+18.80%BeatN/A213 up, 3 downNov 4, 2026$197.56M
    Jun 30, 2026-$2.34-$1.93-$2.34 - -$1.89-21.24%MissN/A160 up, 3 downAug 5, 2026N/A
    Mar 31, 2026-$2.29-$1.84-$1.96 - -$1.61-24.46%MissN/A15N/AMay 6, 2026N/A
    Dec 31, 2025-$1.86-$1.58-$1.70 - -$1.15-17.72%MissN/A151 up, 0 downFeb 25, 2026N/A
    Sep 30, 2025-$1.61-$1.39-$1.58 - -$1.15-15.83%MissN/A160 up, 1 downNov 5, 2025N/A
    Jun 30, 2025-$1.31-$1.12-$1.18 - -$1.02-16.96%MissN/A80 up, 1 downAug 6, 2025N/A
    Mar 31, 2025-$1.13-$1.06-$1.16 - -$0.89-6.60%MissN/A80 up, 2 downMay 7, 2025N/A
    Dec 31, 2024-$1.12-$0.96-$1.06 - -$0.79-16.12%MissN/A113 up, 0 downFeb 26, 2025$261.59M
    Sep 30, 2024-$0.94-$0.88-$0.97 - -$0.77-6.82%MissN/A150 up, 1 downNov 6, 2024N/A
    Jun 30, 2024-$0.81-$0.76-$0.84 - -$0.70-6.58%MissN/A151 up, 0 downAug 7, 2024N/A
    Mar 31, 2024-$0.70-$0.72-$0.85 - -$0.67+2.78%BeatN/A110 up, 0 downMay 8, 2024N/A
    Dec 31, 2023-$1.14-$0.88-$1.10 - -$0.70-29.55%MissN/A111 up, 0 downFeb 26, 2024$742000
    Sep 30, 2023-$0.99-$1.00-$1.05 - -$0.94+1.00%BeatN/A80 up, 0 downNov 6, 2023N/A
    Jun 30, 2023-$0.92-$0.82-$0.88 - -$0.77-12.20%MissN/A80 up, 1 downAug 8, 2023$3.82M
    Mar 31, 2023-$0.72-$0.80-$0.92 - -$0.69+10.00%BeatN/A82 up, 0 downMay 8, 2023$7.01M
    Dec 31, 2022-$0.63-$0.82-$0.90 - -$0.68+23.17%BeatN/A100 up, 0 downFeb 27, 2023$13.79M
    Sep 30, 2022-$0.87-$0.85-$1.02 - -$0.71-2.35%MissN/A90 up, 0 downNov 7, 2022$3.36M
    Jun 30, 2022-$0.82-$0.84N/A+2.38%BeatN/AN/A0 up, 0 downAug 9, 2022$9.12M
    Mar 31, 2022-$0.78-$0.77-$0.88 - -$0.68-1.30%MissN/A60 up, 0 downMay 9, 2022$7.58M
    Dec 31, 2021-$0.71-$0.64-$0.72 - -$0.55-10.94%MissN/A7N/AFeb 28, 2022$9.46M
    Sep 30, 2021-$0.72-$0.62-$0.66 - -$0.57-16.13%MissN/A61 up, 0 downNov 10, 2021$1.10M
    Jun 30, 2021-$0.60-$0.56-$0.60 - -$0.51-7.14%MissN/A6N/AAug 11, 2021$8.70M
    Mar 31, 2021-$0.53-$0.52-$0.56 - -$0.46-1.92%MissN/A5N/AMay 10, 2021$10.13M
    Dec 31, 2020-$0.52-$0.38-$0.45 - -$0.22-36.84%MissN/A5N/AMar 2, 2021$8.75M
    Sep 30, 2020-$0.42-$0.40-$0.44 - -$0.34-5.00%MissN/A5N/ANov 12, 2020$12.66M
    Jun 30, 2020-$0.46-$0.37-$0.40 - -$0.33-24.32%MissN/A5N/AAug 10, 2020$10.03M
    Mar 31, 2020-$0.74-$0.36-$0.41 - -$0.28-105.56%MissN/A4N/AMay 14, 2020$11.55M
    Dec 31, 2019-$6.52-$0.41-$0.62 - -$0.26N/AN/AN/A3N/AFeb 13, 2020$12.09M
    Sep 30, 2019-$0.37N/AN/AN/AN/AN/AN/AN/ANov 27, 2019$12.51M
    Last 29 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.91, after -$3.57 the year before. It was -$6.89 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.91N/A
    Dec 31, 2024-$3.57N/A
    Dec 31, 2023-$3.77N/A
    Dec 31, 2022-$3.10N/A
    Dec 31, 2021-$2.56N/A
    Dec 31, 2020-$2.14N/A
    Dec 31, 2019-$6.89N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,600 words across 21 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,63921
    2026Q2Jun 30, 20267,54018
    2026Q1Mar 31, 20265,41722
    2025Q4Dec 31, 20257,20922
    2025Q3Sep 30, 20257,19622
    2025Q2Jun 30, 20256,39617
    2025Q1Mar 31, 20257,45412
    2024Q4Dec 31, 20248,56516

    2026Q3 Earnings Call

    Opening remarks

    Ryan Asay Senior Vice President, Corporate Affairs Thank you, and welcome, everyone, to the Third Quarter 2026 Earnings Call. Joining me on today's call are Dr. Mark A. Goldsmith, Revolution Medicines' Chairman and Chief Executive Officer; Anthony Mancini, our Chief Global Commercialization Officer; Dr. Alan Bart Sandler, our Chief Development Officer; and Jack Anders, our Chief Financial Officer. Dr. Wei Lin, our Chief Medical Officer, will join us for the Q&A portion of today's call. I would like to inform you that certain statements we make during this call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our recent periodic report filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended September 30, 2026, and recent corporate updates. The press release and updated corporate presentation are available on the Investors section of our website at revmed.com. With that, I will turn the call over to our Chief Executive Officer, Dr. Mark A. Goldsmith. Mark?

    Mark A. Goldsmith Chairman and Chief Executive Officer Thank you, Ryan, and good afternoon, everyone. I will begin today with several remarks focused on our progress in pancreatic cancer and across our broader RAS(ON) portfolio. Anthony will then provide an update on the initial launch of RAS(ON)Q. Alan will discuss progress across our clinical development programs, and Jack will review our third-quarter financial results before I return with brief concluding remarks. The third quarter marked a transformational period for Revolution Medicines. On August 26, less than two years after enrollment began in the global randomized RASolute 302 clinical trial, the FDA approved RAS(ON)Q for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy. We immediately began making it available by prescription in the United States. The approval provided an important regulatory proof point for our RAS(ON) approach and marked the beginning of a new chapter for our company. More importantly, eligible patients and their physicians now have an approved oral targeted medicine designed to directly and broadly inhibit RAS, the main cause of pancreatic cancer, in a disease with a profound need for therapeutic breakthroughs. This milestone reflects years of scientific conviction, disciplined development, and focused execution by our team and collaborators. It also formally opens the delivery phase of responsibility for Revolution Medicines. We are working tirelessly to execute the U.S. launch with urgency, help eligible patients access daraxonrasib promptly, support a positive treatment experience, and rigorously prepare to expand the launch internationally. With the U.S.

    Frequently Asked Questions About RVMD

    When is Revolution Medicines's next earnings date?

    Revolution Medicines's next earnings report is expected for Feb 23, 2027.

    Did RVMD beat earnings estimates last quarter?

    Yes. Revolution Medicines reported EPS of -$1.90 for the quarter ended Sep 30, 2026, above the -$2.34 estimate, a 18.80% surprise.

    What EPS do analysts expect from RVMD next quarter?

    The consensus EPS estimate for Revolution Medicines for the quarter ending Dec 31, 2026 is -$1.87 from 25 analysts, with estimates from -$3.46 to -$0.85.

    How often does RVMD beat earnings estimates?

    Revolution Medicines beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -12.52%.